Nexavar Gets Fast Track FDA Designation For Skin Cancer

Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar(R) (sorafenib) tablets has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced (including locally unresectable and metastatic) melanoma, a form of skin cancer. Nexavar was approved by the FDA in December 2005 for the treatment of patients with advanced renal cell carcinoma (RCC).
